In this issue:
Bimekizumab vs adalimumab for plaque psoriasis
Bimekizumab in moderate-tosevere hidradenitis suppurativa
Guselkumab for palmoplantar pustulosis
Long-term risankizumab for moderate-to-severe plaque psoriasis
Safety and benefit-risk of treatments for moderate-to-severe plaque psoriasis
Predictors of secondary infliximab failure in Japanese psoriasis patients
Comparison of IL-23, IL-17, and TNF-α inhibitors for psoriasis
Telemedicine versus in-person visit among patients with psoriasis
Omalizumab for chronic urticaria in paediatric patients
Dupilumab for elderly patients with atopic dermatitis
Please login below to download this issue (PDF)